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631REPLY: 18F-FDG Imaging in Patients With
“Suspected,” But Not “Proven,” SarcoidosisWe thank Drs. Njeim, Bogun, and Crawford for
their interest in our study (1). We agree that in the
absence of histological conﬁrmation of sarcoidosis,
it is possible that there may be other chronic inﬂam-
matory processes that could have a similar presenta-
tion, hence, our designation in the title “suspected
cardiac sarcoidosis.” Patients with this constellation of
ﬁndings who lack a histological diagnosis are as
common as those with a histological diagnosis and
raise difﬁcult management issues. We would note
the following: 1) the vast majority of events in patients
with abnormal positron emission tomography (PET)
studies occurred in patients with known or a high
likelihood of cardiac sarcoidosis (see the Online Ap-
pendix in our original paper [1]); 2) none of the patients
in our study had known acute myocarditis (e.g.,
elevated cardiac enzymes), and although scar from
prior episodes of myocarditis may cause arrhythmias,
this would not result in increased FDG uptake; and 3)
none of the patients with increased FDG had other
potential alternative reasons for such ﬁndings such as
coronary artery disease or any known systemic in-
ﬂammatory or rheumatologic disease. Even in the
absence of a histological diagnosis (which cannot
always be obtained in cardiac sarcoidosis), abnormal
PET ﬁndings were associated with a substantial in-
crease in the rate of death/ventricular tachycardia.
The high event rate observed in our study is in
part due to referral bias, because our center is a
quaternary care center for advanced heart failure
and arrhythmias. As expected, our study therefore
included patients with a prior history of arrhythmias.
It is also noteworthy that the high event rate observed
in our study is in keeping with data from Schuller
et al. (2), who reported that appropriate implantable
cardioverter-deﬁbrillator (ICD) therapies occurred in
36 (32%) of 112 patients with cardiac sarcoidosis over
a mean of 29 months, and from Betensky et al. (3),
who reported ICD therapies in 17 (38%) of 45 patients
with cardiac sarcoidosis followed over a median of
2 years. In regard to events in patients with normal
PET, we would point out that we used PET only to
evaluate for inﬂammation or scar, and that it does
not exclude nonischemic cardiomyopathy. In fact,
all of the 6 patients with a normal PET scan who
experienced events had systolic dysfunction. There-
fore, if we were to deﬁne a “normal PET” as also
having a normal left and right ventricular function,
there would be zero events in this category.
In regard to the low prevalence of extracardiac
sarcoidosis, it is important to note that we reportedthe frequency of extracardiac FDG uptake (which
represents active inﬂammation) as distinguished
from other radiological evidence of disease that
may represent scar from inactive disease. However,
even when accounting for the fact that patients
without extracardiac FDG uptake may have had prior
extracardiac sarcoidosis, we do believe that the
presence of isolated cardiac sarcoidosis is under-
recognized. In part, this is because prior clinical
criteria, as well as most prior imaging studies, have
only included patients with conﬁrmed extracardiac
disease. We believe that future criteria should
address the fact that cardiac sarcoidosis can be pre-
sent (and therefore should be diagnosed) even in
patients without extracardiac disease. We also agree
that a prospective study is needed to deﬁne the role
of PET in selection of therapy for this challenging
group of patients.*Ron Blankstein, MD
Michael T. Osborne, MD
Alfonso H. Waller, MD
Venkatesh L. Murthy, MD, PhD
Sharmila Dorbala, MD, MPH
William G. Stevenson, MD
Marcelo F. Di Carli, MD
*Cardiovascular Division and Department of Radiology
Brigham and Women’s Hospital
75 Francis Street
Room Shapiro 5096
Boston, Massachusetts 02115
E-mail: rblankstein@partners.org
http://dx.doi.org/10.1016/j.jacc.2014.05.023
REF ER ENCES
1. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomog-
raphy enhances prognostic assessments of patients with suspected cardiac
sarcoidosis. J Am Coll Cardiol 2014:63329–36.
2. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter deﬁbril-
lator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol
2012;23:925–9.
3. Betensky BP, Tschabrunn CM, Zado ES, et al. Long-term follow-up of
patients with cardiac sarcoidosis and implantable cardioverter-deﬁbrillators.
Heart Rhythm 2012;9:884–91.High Sensitivity
Cardiac Troponin T
Testing Time Is Also a Learning TimeHigh-sensitivity cardiac troponin T (hs-cTnT) is
excellent for the early diagnosis of myocardial
infarction (1). In a recent issue of the Journal,
Bandstein et al. (2) validated again the outstanding
